Drugs / RM-131
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy6 trials | ||||||
| Phase 1 | NCT02137642 Comparator | Aug → Nov 2014 | constipation disorder | Motus Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01394055 Comparator | Jul 2011 → Nov 2012 | diabetes mellitus, gastroparesis, intestinal motility disease | Motus Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01955616 Comparator | Sep 2013 → May 2015 | Parkinson disease | Motus Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT01781104 Comparator | Mar 2013 → Sep 2014 | constipation disorder | Motus Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01642550 Comparator | Nov 2012 → Mar 2015 | anorexia nervosa | Motus Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01571297 Comparator | Apr 2012 → Aug 2013 | diabetes mellitus, gastroparesis | Motus Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RM-131 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01571297 ↗ |
| Action | Activate | “ghrelin agonist” PMID 23639598 ↗ Apr 2013 |
| Route | Subcutaneous | “100 μg subcutaneously once” NCT01394055 ↗ |